Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01436734

Enrollment

Registered

2011-09-20

Start date

2011-07-31

Completion date

2013-05-31

Last updated

2015-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglucagonemia

Brief summary

The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced in human plasma samples after oral glucose stimulation, also in fasted and hypoglycemia blood samples from patients' type 2 diabetes. Since, the structure and the techniques for the glucagon measurement are well described nowadays.

Interventions

OTHERFasting glycemia

no intervention

OTHERHypoglycemia

Insulin induced hypoglycemia

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Caucasians 18 years or older with Type 2 diabetes (WHO criteria)

Exclusion criteria

* HbA1c \>9 % * Liver disease (ALAT/ASAT \>2 x upper normal limit) * Diabetic nephropathy (s-creatinine \>130 µM or albuminuria) * Proliferative diabetic retinopathy (anamnestic) * Severe arteriosclerosis or heart failure (NYHA group III og IV) * Anemia * treatment with medication not applicable to pause for 12 hours * pregnancy or lactation * Fasting plasma glucose \>15 mM on screening day.

Design outcomes

Primary

Measure	Time frame
Change in plasma glucagon values measured with c-terminal specific micro-protocol RIA4305: 350µl of plasma (duplicate sample).	120 min

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026